Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Allergy ; 75(1): 75-83, 2020 01.
Article in English | MEDLINE | ID: mdl-31306491

ABSTRACT

BACKGROUND: An investigator-driven, real-life follow-up study of adult-onset steroid-naïve, newly diagnosed asthma (162 patients) to investigate the treatment results over the 25-year course of the disease and whether the first treatment year's forced expiratory volume in one second (FEV1 ) predicts the long-term prognosis. METHODS: Eighty-three per cent of the 133 living patients participated in the 25-year examinations. At this visit, basic asthma examinations including lung function, as well as questionnaires for health-related quality of life (HRQoL), GINA and the Asthma Control Test, were used for evaluation. The use of medication and remission was verified. RESULTS: There was no statistically significant change in mean FEV1 % predicted (FEV1 %) from baseline to the 25-year control. The changes in FEV1 % during the first year predicted the results at the end of follow-up. Normal FEV1 % at the end of the first year predicted normal FEV1 , and below-normal FEV1 % at 1 year predicted below-normal FEV1 % at 25 years. Twenty-nine patients (26.4%) had discontinued their medication, and six (5.5%) used ICS periodically. Clinical remission was reached by 16.4% of the patients, and 7.6% reached functional remission. The general HRQoL remained unchanged. CONCLUSION: In adult-onset asthma, the level of FEV1 reached during the first treatment year seems to predict the later lung function level. One quarter of the patients discontinued the asthma treatment, but their HRQoL was better than that of those continuing to use ICS. Clinical remission was reached by 16% of the patients, which is in concordance with other studies.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Quality of Life , Treatment Outcome , Adult , Age of Onset , Disease Progression , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , Prospective Studies , Respiratory Function Tests , Time
2.
Duodecim ; 131(5): 495-6, 2015.
Article in Finnish | MEDLINE | ID: mdl-26237912

ABSTRACT

Pneumonia is recognised in patients suffering from acute cough or deteriorated general condition. Patients with acute cough without pneumonia-related symptoms or clinical findings do not benefit from antimicrobial treatment. Those with suspected or confirmed pneumonia are treated with antibiotics, amoxicillin being the first choice. Most patients with pneumonia can be treated at home. Those with severe symptoms are referred to hospital. Patients are always encouraged to contact his/her physician if the symptoms worsen or do not ameliorate within 2-3 days. Patients aged 50 years or older and smokers are controlled by thoracic radiography in 6-8 weeks.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cough/diagnosis , Cough/drug therapy , Pneumonia/diagnosis , Pneumonia/drug therapy , Acute Disease , Adult , Age Factors , Female , Humans , Male , Risk Factors
3.
Duodecim ; 129(1): 80-5, 2013.
Article in Finnish | MEDLINE | ID: mdl-23431886

ABSTRACT

A seventyseven-year old woman had a history of osteomyelitis in the 1940s. Now, she was investigated for an antibiotic resistant fever. An unusual infection, an autoimmune disease or a malignancy was suspected. In the CT scan a mediastinal mass was detected and a mediastinoscopy was performed. Histology revealed a granulomatous infection but a tuberculous infection was ruled out. A favourable response to ordinary antibiotics was gained and the diagnosis of tularemia was confirmed by a serologic test.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Mediastinal Diseases/diagnosis , Mediastinal Diseases/drug therapy , Tularemia/diagnosis , Tularemia/drug therapy , Aged , Diagnosis, Differential , Female , Fever , Humans , Tomography, X-Ray Computed
4.
Hum Immunol ; 73(1): 93-100, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22074998

ABSTRACT

Sarcoidosis is a multiorgan immune-mediated disease of unknown etiology with varying clinical pictures. We studied 3 genes in the major histocompatibility complex region (HLA-DRB1 and complement C4A and C4B) in patients with resolved disease after a 2-year follow-up (n = 90) and in patients whose disease was still active at that time point (n = 98) and compared them with controls (n = 150). Our primary aim was to detect genetic differences between the patient groups. We observed that the susceptibility allele for sarcoidosis was HLA-DRB1*15:01 (p = 0.011; odds ratio [OR] = 1.67) and the protective allele was HLA-DRB1*01:01 (p = 0.001; OR = 0.43). HLA-DRB1*03:01 was associated with resolving disease when compared with the persistent group (p = 0.011; OR = 2.22). The probability of having resolving disease was even greater if the patient had HLA-DRB1*03:01 and did not have extrapulmonary lesions (p = 0.001; OR = 3.39). By evaluating amino acid variants of the HLA-DRB1 gene, we determined that specific amino acids in pockets 4, 7, and 9 were associated with the prognosis of sarcoidosis. Our results support the importance of HLA-DRB1 as a predisposing gene for sarcoidosis. Particularly, HLA-DRB1*03:01 and polymorphisms of DRB1 pocket residues were associated with a favorable prognosis. Thus, accurate categorization of disease phenotype and HLA-DRB1 sequencing offer a basis for disease course estimation of sarcoidosis.


Subject(s)
Complement C4a/genetics , Complement C4b/genetics , HLA-DRB1 Chains/genetics , Sarcoidosis/genetics , Adult , Alleles , Complement C4a/deficiency , Complement C4b/deficiency , DNA Copy Number Variations , Female , Finland , Gene Frequency , Genetic Predisposition to Disease/genetics , Genotype , Haplotypes , Humans , Linkage Disequilibrium , Logistic Models , Male , Middle Aged , Prognosis , Sarcoidosis/metabolism , Sarcoidosis/pathology , Young Adult
5.
J Asthma ; 48(9): 945-51, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21958380

ABSTRACT

OBJECTIVE: We assessed the 10-year effectiveness of self-management guidance in a prospective follow-up study of patients with asthma when inhaled corticosteroids were used from the beginning in the treatment. METHODS: Consecutive newly diagnosed asthmatics (n = 162) were randomized: 80 to an intervention group (IG) and 82 to a control group (CG). Lung function (LF), airway hyperresponsiveness (AHR), and health-related quality of life (HRQoL) were examined at 10 years. RESULTS: The advantages of intensive education with regards to LF measured by forced expiratory volume in 1 second and forced vital capacity were seen only after the first year. Later, there were no statistically significant differences in any parameters between the groups. However, during 10-year follow-up, peak expiratory flow, AHR, and HRQoL improved significantly in both groups (no differences as regards gender, smoking, or atopy). At 10 years, 68% of the IG and 75% of the CG patients still showed AHR after histamine challenge. Generic HRQoL scores in both groups equaled that of the age-standardized group a general population but only 50% in the IG and 55% in the CG had normal disease-specific HRQoL scores. According to Global Initiative for Asthma (GINA) criteria 23% of patients in the IG and 25% in the CG had asthma under control. CONCLUSIONS: The effectiveness of intensive self-management education could be shown only in the short term. The groups did not differ significantly in any of the parameters investigated, and showed nearly normal LF and HRQoL. AHR improved only partly and only a minority of the patients had asthma under good control according to GINA criteria. This study showed that evaluation of asthma using LF alone does not show the whole truth about asthma treatment results. HRQoL should be used in conjunction with GINA criteria, to assess asthma treatment outcomes. The value and importance of AHR for the evaluation of treatment remains obscure.


Subject(s)
Asthma/therapy , Patient Education as Topic , Self Care/methods , Adult , Female , Follow-Up Studies , Humans , Male , Prospective Studies , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...